--Ocular Therapeutix, Inc., an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the first patient has been randomized in the HELIOS-3 Phase 3 ...
The MarketWatch News Department was not involved in the creation of this content. SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or ...
Seven students from the Northeast Valley graduated July 24 from the 2015 Helios Scholars summer internship program at the Translational Genomics Research Institute, or TGen, in Phoenix. Helios ...
BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...
First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, ...
“The HELIOS program has the potential to transform care for patients with diabetic retinal disease, and my patients are excited to participate in this study. Current DR treatments are burdensome and ...
First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, ...
(MENAFN- GlobeNewsWire - Nasdaq) First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results